Article

Addition Technology adds acquired products to Intacs line

Addition Technology Inc. has acquired CooperVision Surgical’s AlphaCor and AlphaSphere and plans to add these products to the Intacs line of corneal implants.

Addition Technology Inc. has acquired CooperVision Surgical’s AlphaCor and AlphaSphere and plans to add these products to the Intacs line of corneal implants.

AlphaCor is a flexible, biointegratable, one-piece artificial cornea designed to replace scarred or diseased native cornea. The product is for patients who have had not responded favorably to multiple corneal transplants and for those patients for whom a donor graft is likely to fail.

AlphaSphere is a soft-biocompatible orbital implant that the company plans to launch later this year. The product is FDA approved for treatment of patients who have lost an eye due to disease or trauma.

Intacs is the only additive corneal implant approved by the FDA for both keratoconus and myopia.

In other news, Addition Technology announced a 55% increase in second quarter 2006 sales of its corneal implants compared with the same quarter the previous year and a 20% increase over the first quarter 2006.

The company has had 13 consecutive quarters of double-digit growth in the United States and international markets.

“With any new technology, the adoption rate builds based upon successful patient outcomes experienced by surgeons,” said William M. Flynn, president and CEO of Addition Technology. “Internationally, we have a strong, technically-oriented distributor network that continues to aggressively train and assist a broad group of corneal surgeons.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.